Why hormone tests are often normal in perimenopause

Hormone tests come back normal in perimenopause because perimenopause is not a state of low hormones. It is a state of unstable hormones. FSH and estradiol swing from cycle to cycle and even week to week, so a single blood draw captures one point on a jagged line. That is why US and international guidance diagnoses perimenopause from your age, your cycle pattern and your symptoms, and reserves blood tests for specific situations.

What the tests measure

FSH (follicle-stimulating hormone) is the brain’s signal to the ovaries. As the number of ovarian follicles falls, the ovaries produce less inhibin B, the hormone that normally restrains FSH, so FSH rises to push harder. A high FSH is a sign the ovaries are responding less readily.

Estradiol is the main estrogen produced by the ovaries. It is low in menopause, but in perimenopause it can be normal or even high.

AMH (anti-Müllerian hormone) is produced by small follicles and tracks the size of the remaining follicle pool. It falls steadily with age and becomes very low as menopause approaches.

None of these is a test for perimenopause. They are snapshots of a system that is, by definition, fluctuating.

Why a normal result does not rule it out

FSH rises early but erratically. STRAW+10 describes FSH in the early transition as elevated but variable. In the late transition, it says FSH is sometimes elevated into the menopausal range and sometimes within the range characteristic of the earlier reproductive years, particularly when estradiol is high. The same woman can test “menopausal” in March and “normal” in May.

Estrogen holds up longer than people expect. In SWAN, which measured FSH and estradiol annually in 1,215 women through their final period, the average FSH began rising about 6 years before the final period and accelerated about 2 years before it. Average estradiol did not begin to fall until about 2 years before the final period, reached its fastest decline at the final period, and stabilized about 2 years after. For most of perimenopause, then, estradiol on average is not low.

Estrogen can surge. Researchers who sampled blood three times a week found that in 37% of ovulatory cycles during the transition, estradiol rose a second time in the luteal phase and peaked around the next period, a pattern they called a luteal out-of-phase event, apparently triggered by high FSH recruiting a new follicle too early. These cycles had lower progesterone and were linked to short or long cycle lengths. A blood test during such a surge shows high estrogen and may show suppressed FSH, the opposite of what people expect from perimenopause.

Hormone	What people expect in perimenopause	What studies actually show
FSH	Consistently high	Elevated on average but swinging; can be normal in the same woman weeks later
Estradiol	Low	Average unchanged until about 2 years before the final period; surges common
Progesterone	Low	Low or absent in anovulatory cycles, normal in ovulatory ones
AMH	Low	Falls steadily; the most consistent marker, but not a diagnosis

How perimenopause is actually diagnosed

The STRAW+10 staging system, the standard used in research and clinical practice, defines the transition by bleeding patterns:

• Early transition: cycle length varies by 7 or more days between consecutive cycles, recurring within 10 cycles
• Late transition: 60 or more days without a period

FSH appears only as a supportive criterion. STRAW+10 notes that an FSH above 25 IU/L on a random draw is characteristic of the late transition, and in the same breath cautions that researchers and clinicians should evaluate the appropriate value for the assay they use. It also recommends that staging be applied regardless of a woman’s age, ethnicity, body size or lifestyle.

For a woman in her mid-40s with cycles that have started to vary, plus night sweats, broken sleep or mood change, the diagnosis is made from that history. Our guide to what perimenopause is walks through the symptom picture, and the symptom check helps organize it.

When testing does help

Under 40. Irregular or absent periods before 40 raise the question of primary ovarian insufficiency, and here blood tests are essential. ACOG recommends measuring FSH and estradiol along with tests for pregnancy, thyroid disease and high prolactin. If FSH is in the menopausal range, typically above 30 to 40 mIU/mL depending on the laboratory, it is repeated in 1 month before the diagnosis is made. An estradiol below 50 pg/mL indicates low estrogen.

Ruling out look-alikes. Thyroid disease, pregnancy, high prolactin and iron deficiency all produce symptoms that overlap with perimenopause. Those tests are worth doing at any age when the picture is unclear.

No periods to go by. Women who have had a hysterectomy or endometrial ablation cannot be staged by bleeding. STRAW+10 notes that in these women staging relies on hormone markers, that clinicians should wait at least 3 months after pelvic surgery because surgery can transiently raise FSH, and that a single FSH and estradiol sample may be ambiguous or misleading, so at least one repeat is often required.

On hormonal contraception. Tests are not interpretable. ACOG states FSH and estradiol should only be measured in women not taking hormonal medications, including oral contraceptives. Clinicians typically use age to guide decisions about stopping contraception instead.

What about the AMH test?

AMH is the most promising marker because it falls more steadily than FSH. In SWAN, 1,537 women averaging 47.5 years had AMH and FSH measured repeatedly until menopause. AMH predicted the timing of the final period better than FSH. A woman with an AMH below 10 pg/mL had a 51% chance of her final period within 12 months if she was under 48, rising to 79% if she was 51 or older. A woman with an AMH above 100 pg/mL had a 97% chance of not reaching her final period within a year if under 48, and 90% if 51 or older.

In 2018 the FDA permitted marketing of the first AMH test specifically as an aid in determining menopausal status, based on data from 690 SWAN participants aged 42 to 62. The FDA’s own framing is the important part: the test is meant to be used only in conjunction with other clinical assessments and laboratory findings. It warned that results should not be used to stop contraception in women who have not reached menopause, or to dismiss uterine bleeding that could be endometrial cancer, and that it should not be used to assess fertility.

So AMH can help estimate how close menopause is, especially in the late 40s and early 50s. It does not diagnose perimenopause, and it does not replace the calendar.

What to ask for instead

• A review of your cycle history over the past year or two, with dates if you have them
• A symptom review, including sleep, mood, hot flashes, bleeding changes and vaginal symptoms
• Targeted tests to rule out other causes: TSH, a complete blood count and ferritin if periods are heavy or you are exhausted, a pregnancy test if there is any possibility
• FSH, estradiol and prolactin if you are under 40 or have no periods to go by
• A treatment plan based on symptoms, not on a number

When to see a clinician

• You are under 40 and your periods have become irregular for 3 or more months or stopped for 4 months
• Your symptoms are being dismissed because a hormone test came back normal
• You have bleeding between periods, after sex, heavier or longer than usual, or any bleeding after 12 months without a period
• You are soaking through a pad or tampon every hour for 2 or more hours in a row, especially with dizziness or shortness of breath: seek same-day care
• You are unsure whether you still need contraception

If early waking is your most troubling symptom, see why perimenopause wakes you at 3 am. For help finding a clinician who diagnoses perimenopause clinically rather than by a single lab value, read how to find a menopause specialist or search for an ob-gyn near you.